Form 4: CG Oncology Director Sells 700,000 Shares in Public Offering

A CG Oncology director, Hong Fang Song, indirectly sold 700,000 shares of common stock at $28 per share through Charming Jade Limited as part of a public offering.

Summary

• Hong Fang Song, a director at CG Oncology, indirectly sold 700,000 shares of common stock at $28 per share.
• The sale was executed through Charming Jade Limited, a wholly-owned subsidiary of ORI Healthcare Fund II, L.P.
• The transaction occurred as part of CG Oncology's public offering, which closed on December 16, 2024.
• Following the transaction, Ms. Song still indirectly owns 3,003,931 shares through Charming Jade Limited and 586,982 shares through Unique Diamond Investments Limited.
• She also directly owns 613,928 shares of CG Oncology common stock.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing for an insider share sale, which is neither positive nor negative in itself.

Industry Context

This transaction is a standard disclosure for a director selling shares in a public offering. It is common for insiders to sell shares after a company goes public.

Comparison to Industry Standards

• Sales by directors following a public offering are common and this transaction is not unusual.
• The sale of 700,000 shares is not particularly large compared to other insider sales after IPOs.
• The price of $28 per share is the price of the public offering.

Stakeholder Impact

• The sale may have a minor impact on shareholder sentiment, but is not unexpected after a public offering.

Key Dates

Keywords

CG Oncology, Hong Fang Song, Charming Jade Limited, public offering, share sale, director, ORI Healthcare Fund, common stock, insider trading